These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 30089717)

  • 1. SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy.
    Cassis P; Locatelli M; Cerullo D; Corna D; Buelli S; Zanchi C; Villa S; Morigi M; Remuzzi G; Benigni A; Zoja C
    JCI Insight; 2018 Aug; 3(15):. PubMed ID: 30089717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.
    Zhang Y; Thai K; Kepecs DM; Gilbert RE
    PLoS One; 2016; 11(1):e0144640. PubMed ID: 26741142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
    Cha JJ; Park HJ; Yoo JA; Ghee J; Cha DR; Kang YS
    Kidney Blood Press Res; 2024; 49(1):81-90. PubMed ID: 38185119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
    Rajasekeran H; Reich HN; Hladunewich MA; Cattran D; Lovshin JA; Lytvyn Y; Bjornstad P; Lai V; Tse J; Cham L; Majumder S; Bowskill BB; Kabir MG; Advani SL; Gibson IW; Sood MM; Advani A; Cherney DZI
    Am J Physiol Renal Physiol; 2018 Mar; 314(3):F412-F422. PubMed ID: 29141939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephropathy in diabetic db/db mice is accelerated by high protein diet and improved by the SGLT2 inhibitor dapagliflozin.
    Nørgaard SA; Briand F; Sand FW; Galsgaard ED; Søndergaard H; Sørensen DB; Sulpice T
    Eur J Pharmacol; 2019 Oct; 860():172537. PubMed ID: 31310751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.
    Yaribeygi H; Butler AE; Atkin SL; Katsiki N; Sahebkar A
    J Cell Physiol; 2018 Jan; 234(1):223-230. PubMed ID: 30076706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes.
    Birnbaum Y; Bajaj M; Yang HC; Ye Y
    Cardiovasc Drugs Ther; 2018 Apr; 32(2):135-145. PubMed ID: 29508169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of sodium/glucose cotransporter inhibition on a rat model of angiotensin II-dependent kidney damage.
    Reyes-Pardo H; Bautista R; Vargas-Robles H; Rios A; Sánchez D; Escalante B
    BMC Nephrol; 2019 Aug; 20(1):292. PubMed ID: 31375080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.
    Chu C; Lu YP; Yin L; Hocher B
    Kidney Blood Press Res; 2019; 44(2):149-157. PubMed ID: 30939483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Effect of Sodium Glucose Co-Transporter 2 Inhibitor Dapagliflozin on Renal Cell Carcinoma.
    Kuang H; Liao L; Chen H; Kang Q; Shu X; Wang Y
    Med Sci Monit; 2017 Aug; 23():3737-3745. PubMed ID: 28763435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes.
    Shin SJ; Chung S; Kim SJ; Lee EM; Yoo YH; Kim JW; Ahn YB; Kim ES; Moon SD; Kim MJ; Ko SH
    PLoS One; 2016; 11(11):e0165703. PubMed ID: 27802313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.
    Oe Y; Kim YC; Sidorenko VS; Zhang H; Kanoo S; Lopez N; Goodluck HA; Crespo-Masip M; Vallon V
    Am J Physiol Renal Physiol; 2024 Feb; 326(2):F227-F240. PubMed ID: 38031729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Sodium-Glucose Cotransporter 2 Inhibitor Dapagliflozin Prevents Renal and Liver Disease in Western Diet Induced Obesity Mice.
    Wang D; Luo Y; Wang X; Orlicky DJ; Myakala K; Yang P; Levi M
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29301371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
    van Bommel EJM; Geurts F; Muskiet MHA; Post A; Bakker SJL; Danser AHJ; Touw DJ; van Berkel M; Kramer MHH; Nieuwdorp M; Ferrannini E; Joles JA; Hoorn EJ; van Raalte DH
    Clin Sci (Lond); 2020 Dec; 134(23):3107-3118. PubMed ID: 33205810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in
    Korbut AI; Taskaeva IS; Bgatova NP; Muraleva NA; Orlov NB; Dashkin MV; Khotskina AS; Zavyalov EL; Konenkov VI; Klein T; Klimontov VV
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32340263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
    Gal A; Burton SE; Weidgraaf K; Singh P; Lopez-Villalobos N; Jacob A; Malabu U; Burchell R
    Domest Anim Endocrinol; 2020 Jan; 70():106376. PubMed ID: 31585313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the VEGF-A/caveolin-1/PV-1 signaling pathway.
    Locatelli M; Zoja C; Conti S; Cerullo D; Corna D; Rottoli D; Zanchi C; Tomasoni S; Remuzzi G; Benigni A
    J Pathol; 2022 Apr; 256(4):468-479. PubMed ID: 35000230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.